Caption Management, LLC Relmada Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $1.44 Million - $23.8 Million	663,400 Added 294.32%	888,800 $3.1 Million
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $5.96 Million - $12.1 Million	-325,500 Reduced 59.09%	225,400 $8.35 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $4.8 Million - $8.82 Million	290,700 Added 111.72%	550,900 $10.5 Million
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $4.35 Million - $7.02 Million	260,200 New	260,200 $7.02 Million
Q3 2021 Nov 12, 2021	SELL	$21.86 - $34.77 $1.28 Million - $2.03 Million	-58,500 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $1.42 Million - $1.88 Million	47,900 Added 451.89%	58,500 $1.87 Million
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $334,112 - $416,368	10,600 New	10,600 $373,000
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $594,500 - $1.25 Million	-25,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$10.1 - $47.18 $252,500 - $1.18 Million	25,000 New	25,000 $975,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.